Retatrutide 20mg

Retatrutide, 20mg lyophilized powder in a sealed vial. Retatrutide (LY3437943) is an investigational triple agonist of the GLP-1, GIP and glucagon receptors. It is being studied in clinical trials for obesity and type 2 diabetes, where research has examined its effects on body weight, glycemic control and liver fat. It is not an approved medicine.

Research areas

• GLP-1 / GIP / glucagon receptor agonism
• Metabolic and body-weight research
• Glucose regulation
• Hepatic fat in clinical studies

For research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.